CoPARC: Colorado Pulmonary Alcohol Research Collaborative

CoPARC：科罗拉多州肺酒精研究合作组织

• 批准号: 9926794
• 负责人: ELLEN L BURNHAM
• 金额: $ 70.15万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9926794
• 关键词: Acetaldehyde; Acetylcarnitine; Admission activity; Adult Respiratory Distress Syndrome; Alcohol consumption; Alcohols; Aliquot; Alveolar Macrophages; Area; Biocompatible Materials; Blood; Blood specimen; Bronchoalveolar Lavage Fluid; Bronchoscopy; Burn injury; California; Cannabis; Cells; Chicago; Clinical; Collection; Colorado; Communication; Communities; Critical Illness; Data; Data Set; Development; Economic Burden; Emerging Technologies; Endotoxins; Enrollment; Ensure; Epithelial Cells; Equipment and supply inventories; Erythrocytes; Evaluation; Exhalation; Faculty; Fatty Acids; Fostering; Funding; Generations; Genomics; Geography; Goals; Grant; Growth; Health; Histologic; Host Defense; Host Defense Mechanism; Human; Immune system; Immunity; Immunoglobulins; Inflammatory; Infrastructure; Institution; Intensive Care Units; Knowledge; Lipids; Louisiana; Lung; Lung diseases; Malondialdehyde; Marketing; Mechanical ventilation; Medical center; Mission; Monoclonal Antibody R24; Morbidity - disease rate; Nasal Epithelium; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; Nebraska; Needs Assessment; Online Systems; Oropharyngeal; Outcome; Oxidative Stress; Pathology; Patient-Focused Outcomes; Patients; Peripheral Blood Mononuclear Cell; Phospholipids; Plasma; Pneumonia; Production; Proteins; Publications; Recording of previous events; Research; Research Personnel; Research Subjects; Resources; Respiratory Failure; Respiratory System; Risk; Risk Factors; San Francisco; Site; Smoker; Specimen; Strategic Planning; Streptococcus pneumoniae; System; Targeted Research; Taxonomy; Therapeutic Intervention; Time; Tissues; Translational Research; Universities; Urine; adduct; airway epithelium; alcohol effect; alcohol research; alcohol use disorder; antimicrobial peptide; base; biomarker development; burden of illness; career development; clinical material; cytokine; data sharing; genome sequencing; improved; innovation; lung microbiome; marijuana use; microbiome alteration; microbiota; mortality; novel; pathogen; prevent; prophylactic; racial diversity; receptor expression; response; whole genome

Project Summary The goal of this proposal is to seek continued support to augment and sustain an established Alcohol Research Resource, known as CoPARC (Colorado Pulmonary-Alcohol Research Collaborative). CoPARC's mission is to facilitate research that will prevent the development of alcohol-associated pneumonia, ameliorate its deleterious complications, and ultimately improve clinical outcomes. Alcohol use disorders (AUDs) confer an eight-fold increased risk for community-acquired pneumonia. AUDs also increase morbidity for patients with pneumonia, including increasing the risk of respiratory failure necessitating intensive care unit (ICU) admission and mechanical ventilation. Further, AUD-associated pneumonia is frequently complicated by the development of the acute respiratory distress syndrome (ARDS). Centered at the University of Colorado Denver (UCD) and led by Ellen L. Burnham, MD, MS, the CoPARC infrastructure has enabled enrollment of over 370 ambulatory subjects with and without AUDs, and 237 critically ill patients with pneumonia or burn injury, established ARDS risk factors that are more prevalent in patients with AUDs. Resource materials have originated from institutions with a history of NIAAA-funded translational research in alcohol-related pulmonary diseases, including UCD, Emory University (EU), and Loyola University Chicago (LUC); and from the University of California San Francisco (UCSF) with NHLBI support. Presently, thousands of biospecimens have been collected, including bronchoalveolar lavage (BAL) fluid and cell aliquots; bronchial brushings; and blood specimens. To date, 26 investigators from 11 external institutions have utilized over 6100 biospecimens from 92% of the enrolled subjects. For the renewal, 4 sites (EU, LUC, UCSF, and the University of Nebraska Medical Center) and UCD will collect materials for CoPARC. A Steering Committee comprised of investigators from UCD, EU, LUC, Louisiana State University, UNMC, and Thomas Jefferson University will provide rigorous oversight for CoPARC, including prioritization of biospecimen distribution, and ensuring that milestones promoting use of the Resource are achieved. Innovations that are planned include collection of novel specimens such as whole lung explants; expertise in high-throughput genomics applications; access to administrative data sets enriched in patients with alcohol use; and organization of clinical, inventory, and experimental data to foster cross- investigator sharing. Aims for the renewal are in line with the NIAAA's strategic plan to identify mechanisms of alcohol action and alcohol-related pathology to more fully understand how alcohol asserts its effects on human health. They include: 1) expand and diversify clinical and biological materials obtained from ambulatory subjects with AUDs and critically ill patients, along with appropriate controls, 2) engage emerging web-based systems to prioritize data and biospecimen sharing, and streamline communications between investigators as well as the Steering Committee and 3) enhance visibility and marketing to promote the distribution, growth, and sustainability of the Resource.

项目概要 该提案的目标是寻求持续的支持，以增强和维持既定的酒精 研究资源，称为 CoPARC（科罗拉多州肺酒精研究合作组织）。科帕克研究中心 使命是促进预防酒精相关性肺炎发展的研究，改善 其有害的并发症，并最终改善临床结果。酒精使用障碍 (AUD) 会导致 社区获得性肺炎的风险增加八倍。 AUD 还会增加患有以下疾病的患者的发病率： 肺炎，包括增加呼吸衰竭的风险，需要入住重症监护病房 (ICU) 和机械通气。此外，AUD 相关肺炎常常因发展而变得复杂。 急性呼吸窘迫综合征（ARDS）。以科罗拉多大学丹佛分校 (UCD) 为中心 由医学博士、理学硕士 Ellen L. Burnham 领导的 CoPARC 基础设施已支持 370 多名门诊患者注册 有或没有 AUD 的受试者，以及 237 名患有肺炎或烧伤的危重患者，建立了 ARDS AUD 患者中更常见的危险因素。资源素材来源于机构 拥有 NIAAA 资助的酒精相关肺部疾病（包括 UCD）转化研究的历史， 埃默里大学（EU）和芝加哥洛约拉大学（LUC）；和来自加州大学圣 弗朗西斯科（加州大学旧金山分校）在 NHLBI 的支持下。目前，已收集了数千份生物样本，包括 支气管肺泡灌洗 (BAL) 液和细胞等份；支气管刷检；和血液标本。迄今为止，26 来自 11 个外部机构的研究人员使用了来自 92% 的受试者的 6100 多个生物样本 科目。更新时，4 个地点（EU、LUC、UCSF 和内布拉斯加大学医学中心）和 UCD 将为 CoPARC 收集材料。指导委员会由来自 UCD、EU、LUC、 路易斯安那州立大学、UNMC 和托马斯杰斐逊大学将提供严格的监督 CoPARC，包括生物样本分发的优先顺序，并确保促进使用的里程碑 资源已达。计划的创新包括收集新样本，例如全肺 外植体；高通量基因组学应用方面的专业知识；访问丰富的行政数据集 饮酒患者；临床、库存和实验数据的组织，以促进交叉 调查员分享。更新的目标符合 NIAAA 的战略计划，以确定机制 酒精作用和酒精相关病理学，以更全面地了解酒精如何对人类产生影响 健康。它们包括：1）扩大从门诊获得的临床和生物材料并使其多样化 患有 AUD 的受试者和危重患者，以及适当的控制，2) 参与新兴的基于网络的 系统优先考虑数据和生物样本共享，并简化研究人员之间的沟通 以及指导委员会，3) 提高知名度和营销，以促进分销、增长和 资源的可持续性。